RVMD Form 144: Proposed Common Stock Sale

RVMD filed a Form 144 reporting a proposed sale of Common Stock.

Rhea-AI Filing Summary

RVMD filed a Form 144 reporting a proposed sale of Common Stock. The notice lists restricted stock unit grants dated 03/01/2022, 03/01/2023, 03/01/2024, and 03/01/2025 with line-item amounts shown in the excerpt. The filing is a routine sale notice; timing and proceeds treatment are not provided in the excerpt.

Insights

Securities Counsel

Routine Form 144 sale notice listing RSU-originated shares.

The excerpt lists Common Stock tied to restricted stock unit grants on 03/01/2022, 03/01/2023, 03/01/2024, and 03/01/2025

Timing, exact number being offered for sale, and cash‑flow recipient language are not shown in the provided text; subsequent filings or broker confirmations will clarify execution details.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does RVMD's Form 144 mean?

A Form 144 notifies the SEC of an intended sale of restricted or control securities. The excerpt lists RSU grant dates and line-item amounts; it does not state sale timing or proceeds recipient. Further filing details or broker notices will show execution specifics.

Which securities are referenced in the RVMD excerpt?

The excerpt references Common Stock derived from restricted stock unit grants dated 03/01/2022, 03/01/2023, 03/01/2024, and 03/01/2025. Line items show numeric grant counts in the excerpt but not the sale quantity.

Does the Form 144 excerpt show how many RVMD shares will be sold?

The excerpt shows grant-related counts (e.g., 704, 596, 480, 502) but does not explicitly label an aggregate number as the amount to be sold. The filing excerpt does not provide a clear single "shares to be sold" figure or total proceeds.

Will RVMD receive proceeds from the sale in this Form 144?

The excerpt does not state whether the issuer will receive proceeds. Form 144s commonly reflect sales by holders; the cash‑flow treatment is not included in the provided text and requires the complete filing or related disclosure.

Where can I find execution or timing details for the RVMD sale?

Execution timing and sale method are not present in the excerpt. Look for follow-up broker reports, a completed Form 4 or additional SEC submissions that disclose sale dates, quantities sold, and any Rule 10b5-1 plan information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/13/2026 - 07:41 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001849181
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Revolution Medicines, Inc.
SEC File Number	001-39219
Address of Issuer	700 SAGINAW DR REDWOOD CITY CALIFORNIA 94063
Phone	650-481-6801
Name of Person for Whose Account the Securities are To Be Sold	Wang Xiaolin
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE Financial Corporation 3 Edison Drive Alpharetta GA 30005	2282	227264.38	198173397	03/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/01/2023	Restricted stock unit grant	Issuer			704	03/01/2023	Services Rendered
Common Stock	03/01/2024	Restricted stock unit grant	Issuer			596	03/01/2024	Services Rendered
Common Stock	03/01/2025	Restricted stock unit grant	Issuer			480	03/01/2025	Services Rendered
Common Stock	03/01/2022	Restricted stock unit grant	Issuer			502	03/01/2022	Services Rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	03/13/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/17/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)